logo

Pavmed Inc (PAVM)



Trade PAVM now with
  Date
  Headline
4/21/2020 9:35:32 AM PAVmed Gets FDA 510(k) Clearance For Its CarpX Minimally Invasive Carpal Tunnel Device
3/9/2020 9:32:22 AM PAVmed Reports FDA 510(k) Re-submission For Its CarpX Minimally Invasive Carpal Tunnel Device
2/11/2020 9:34:56 AM PAVmed Says FDA Grants Subsidiary Breakthrough Device Designation For Its EsoGuard Esophageal DNA Test
1/13/2020 9:45:48 AM PAVmed Gets Formal Notification Of Nasdaq Continued Listing Compliance
12/13/2019 9:53:24 AM PAVmed Updates On CarpX Clinical Safety Study
6/24/2019 10:58:33 AM PAVmed Receives 510(k) Marketing Clearance For EsoCheck Cell Collection Device
4/12/2019 9:37:53 AM PAVmed Enters Into Agreements For The Sale Of 1.66 Mln Shares In Registered Direct Offering At Price Of $1.00/shr
11/29/2018 7:34:09 AM PAVmed Subsidiary Lucid Diagnostics Files 510(k) Submission With FDA For EsoCheck Cell Collection Device
11/15/2018 7:42:26 AM PAVmed Q3 Loss Per Share $0.12; Non-GAAP Loss Per Share $0.08
8/14/2018 7:35:35 AM PAVmed Posts Q2 Non-GAAP Adjusted Loss Of $2.35 Mln Or $0.12 Per Share
7/11/2018 7:31:16 AM PAVmed Names Shaun O’Neil To Serve As Its First Chief Commercial Officer
6/8/2018 7:33:10 AM PAVmed To Receive $10.4 Mln In Gross Proceeds From Oversubscribed Rights Offering
5/22/2018 7:35:44 AM PAVmed Q1 Loss Per Share $0.21 Vs Loss$0.32 Last Year
5/14/2018 7:34:07 AM PAVmed Subsidiary Lucid Diagnostics Inc. Secures Exclusive Worldwide License For EsoCheck
4/11/2018 7:34:29 AM PAVmed Posts Q4 GAAP Net Income Attributable To Common Stockholders $310K Or $0.02 Per Share
1/25/2018 4:04:33 PM PAVmed Announces Closing Of Over-Allotment Option With Respect To Firm Commitment Common Stock Offering